Trial Profile
A Phase 2, Randomized, Double-blind-placebo-controlled and Open-label-Sevelamer Hydrochloride-controlled, Dose-ranging Study for ASP1585 in Patients With Chronic Kidney Disease(CKD) and Hyperphosphatemia on Hemodialysis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Bixalomer (Primary) ; Sevelamer
- Indications Hyperphosphataemia; Renal failure
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 22 Dec 2014 New trial record